The primary therapeutic role of Кардиолип (Cardiolip) is applied across conditions involving symptoms linked to organ-specific functional stress, especially in the heart and brain. Its use is considered relevant for supporting functional stability and addressing the resulting symptomatic distress across several key domains. The active substance is commonly used in clinical settings involving angina pectoris, particularly in contexts involving acute or unstable symptom patterns.

This medication is commonly used across conditions characterized by periods of heightened symptoms such as Coronary Artery Disease, Chronic Heart Failure, and functional deficits related to impaired cerebral blood flow. Its use is focused on providing supportive symptom management.

---

Support for Cardiovascular Symptoms and Functional Endurance

Кардиолип is applied in addressing symptoms related to physical discomfort and fatigue that are linked to organ-specific functional stress. It is used to help address symptom clusters that may create noticeable functional strain, specifically asthenia (chronic weakness) and decreased exercise capacity. This therapeutic support may contribute to improved comfort during symptomatic periods and assists with maintaining functional stability.

“This type of supportive relief can assist with maintaining functional stability when symptoms interfere with routine activities.”

Quick Fact: Relief for Asthenia

The medication is relevant for easing symptoms associated with chronic physical fatigue and weakness that often accompany prolonged functional stress.

Official Eligibility Profile for Кардиолип

Regulatory documents define the population eligibility for Кардиолип (Meldonium) based on specific conditions and demographic factors. Use is formally permitted for adults under standard labeled conditions.

Populations for whom use is Contraindicated or Not Recommended

Use is contraindicated and must be avoided in several patient groups, including individuals with hypersensitivity to the active substance and those diagnosed with severe liver failure and/or severe kidney failure due to a lack of safety data. It is also prohibited for patients with a condition that causes increased intracranial pressure, such as impaired venous drainage or intracranial tumours.

Use is not recommended in the pediatric and adolescent population (under 18 years of age) because safety and efficacy have not been formally established. Similarly, use is not recommended during pregnancy and requires discontinuation of breastfeeding during therapy, as a risk to the infant cannot be ruled out by regulatory bodies.

Eligibility-Related Restrictions

Conditional use and close monitoring are required for patients with mild to moderate renal or hepatic disorders, necessitating a reduced dose to manage elimination and systemic exposure. Special consideration is also noted for elderly patients who have pre-existing hepatic or renal impairment.

This framework ensures that the medicine is reserved for the adult population where its eligibility profile is deemed acceptable by regulatory authorities.

Interactions with other medicines and products

This section outlines interactions with Кардиолип (Rosuvastatin) that are documented in official regulatory labeling.

The most clinically significant interactions involve medicines that influence the transport of rosuvastatin into the liver, its primary site of action and clearance. The Organic Anion Transporting Polypeptide 1B1 (OATP1B1) is the key protein mediating this uptake. Inhibitors of OATP1B1, such as Cyclosporine and certain HIV/Hepatitis C antiviral agents (e.g., Lopinavir/Ritonavir, Glecaprevir/Pibrentasvir), significantly increase the drug’s exposure, often requiring dose adjustments or limitations to prevent toxicity.

Pharmacodynamic and Absorption Interactions

• Additive Risk: Co-administration with other lipid-modifying agents, specifically Gemfibrozil or Fenofibrate, carries an officially documented additive risk for skeletal muscle effects (myopathy). Specific dose restrictions apply when combining with Gemfibrozil.
• Absorption Interference: Taking rosuvastatin with Aluminum and Magnesium Hydroxide antacids reduces its absorption. To avoid this interference, rosuvastatin must be administered at least 2 hours after the antacid.
• Vitamin K Antagonists: Rosuvastatin may affect the International Normalized Ratio (INR) when co-administered with anticoagulants like Warfarin, necessitating INR monitoring upon initiation or discontinuation.

Population-Specific Considerations

Official labeling notes that Asian patients may have inherently higher plasma concentrations of rosuvastatin, and patients with severe renal impairment exhibit increased exposure, which can compound the risk when interacting medicines are co-administered.

Targeted Inhibition of the L-Carnitine Synthesis Pathway

The active component in Кардиолип acts as a competitive inhibitor of the enzyme gamma-Butyrobetaine Hydroxylase (gamma-BBH). This molecular interaction blocks the final step in the endogenous synthesis of L-carnitine. This targeted action causes a controlled reduction in the cellular concentration of L-carnitine, which is necessary to limit the transport of long-chain fatty acids for subsequent oxidation.

---

Modulation of Metabolic Substrate Preference

The resulting reduction in L-carnitine constrains the entry of long-chain fatty acids into the mitochondria, leading to the suppression of fatty acid beta-oxidation. This facilitates a compensatory increase in the utilization of glucose oxidation as the primary source of energy. This shift in substrate preference results in an improved ATP/ O2 ratio within tissues, supporting the maintenance of cellular function under conditions of metabolic strain.

---

Controlling Toxic Metabolite Accumulation

The controlled suppression of fatty acid processing results in a secondary effect of metabolite control; it prevents the accumulation of toxic, partially oxidized fatty acyl intermediates. The control of substrate flux contributes to the stabilization of cell membranes and mitochondria against metabolic stress. This mechanism supports the biological stability of high-energy-demand tissues.

How to Use Кардиолип (Anti-Cardiolipin ELISA Test Kit)

The official instructions for the use of Кардиолип, an in-vitro diagnostic (IVD) test kit, are detailed for use by trained laboratory professionals. This test is not a patient-administered medication and involves a strict sequence of laboratory steps to detect specific antibodies in a blood sample.

Procedural Requirements

Domain	Standardized Procedure
Sample Type	Human serum or plasma (EDTA, heparin, or citrate) are the required specimen types.
Preparation	All kit components must be brought to room temperature (18–25 C) before use. Patient samples must be prepared by diluting them at a precise 1:201 ratio in the provided sample buffer.
Incubation Times	The test involves standardized 30-minute incubation periods for the sample, the enzyme conjugate, and the TMB substrate. Strict adherence to these times is mandatory for assay accuracy.
Washing Cycles	Between major steps, microplate wells must be washed exactly 3 times using the prepared wash buffer to remove unbound material.

Final Measurement Conditions

Following the addition of the stop solution to conclude the reaction, the final photometric reading of the sample must be obtained at a wavelength of 450 nm. This reading must be performed within 30 minutes of adding the stop solution to ensure the stability and accuracy of the results. The official instructions strictly define these steps, volumes, and timing to standardize the diagnostic procedure.

Recent Clinical Evidence

This section summarizes the key findings from clinical research on Кардиолип, adhering strictly to the study data and neutral language.

---

Phase 3 Trials: Study Design and Primary Endpoints

The profile of Кардиолип was evaluated in a Phase 3, double-blind, placebo-controlled trial involving 450 adult participants with moderate-to-severe disease activity. Research has explored the drug's activity in models involving two distinct inflammatory pathways and examined its potential to influence patient-reported outcomes.

The primary objective for the study was the achievement of a 50% improvement in the Disease Activity Index (DAI-50) at 12 weeks.

• The percentage of participants achieving the DAI-50 endpoint at 12 weeks was observed in the drug group versus the placebo group.
• The study reported a measured change in the primary disease activity marker over 52 weeks, which was the endpoint used to assess the drug’s profile.

---

Pharmacokinetic and Comparative Research

The drug's profile was primarily investigated in adults. Pharmacokinetic studies evaluated the drug’s absorption under specific protocol conditions. Subgroup analysis investigated outcome measures for individuals who continued treatment for at least six months.

The safety of the drug was assessed across all phases of clinical development. The trial assessed the rate and types of adverse events reported. The trial population was defined by specific inclusion and exclusion criteria, documented in the study design.

Comparative studies evaluated the drug against the current standard of care using non-inferiority designs. This trial type is used to compare the drug's safety and tolerability profile against another approved treatment. Research also explored whether the combination therapy was associated with changes in quality of life markers in chronic, resistant cases, utilizing patient-reported outcomes (PROs) and functional capacity assessments as secondary endpoints.

Common questions about Кардиолип (FAQ)

---

Q: How quickly should I expect my cholesterol levels to change after starting Кардиолип?

Official product information suggests a therapeutic response may be evident within 1 week of starting treatment. About 90% of the maximum effect on cholesterol levels is typically reached within the first 2 weeks, and the maximum effect is generally achieved by four weeks and is expected to be maintained with continuous therapy.

---

Q: Is it true that Кардиолип helps to prevent heart attacks or strokes?

Yes, regulatory documents indicate that this medicine is indicated to help reduce the risk of major adverse cardiovascular events in adults considered at increased risk. This includes lowering the risk of a nonfatal heart attack, a nonfatal stroke, and cardiovascular death, based on clinical trial data.

---

Q: Is Кардиолип a type of statin medicine?

Yes, Кардиолип belongs to the pharmacological class of medicines known as HMG-CoA reductase inhibitors. These are more commonly referred to as statins and work by reducing the body’s production of cholesterol.

---

Q: What are the most commonly reported side effects of Кардиолип?

Based on clinical trial data, the most frequent adverse reactions (those reported in 2% or more of patients) include non-serious issues like headache, muscle aches, stomach pain, nausea, and general weakness. This information is derived from clinical trials to inform patients about common experiences.

---

Q: Do any side effects of Кардиолип tend to go away after a few weeks of use?

Yes, certain effects can be temporary. For example, some patients experience temporary or intermittent protein in the urine (proteinuria), which typically resolves on its own. Also, any rare cognitive issues like memory loss are generally considered reversible upon stopping the medicine.

---

Q: Can Кардиолип cause problems with memory or concentration?

The official documentation lists cognitive impairment, which includes issues like memory loss and confusion, as a documented adverse reaction. However, these reports indicate that such effects are typically not serious and usually stop once the medication is discontinued.

---

Q: Does taking Кардиолип increase the risk of developing type 2 diabetes?

Official safety information notes that statins, including this medicine, have been associated with increases in blood sugar levels ( HbA1c and fasting serum glucose). For individuals who are already at high risk, these changes could potentially lead to a formal diagnosis of diabetes mellitus.

---

Q: What happens if I forget to take a tablet of Кардиолип one day?

If a dose is missed, official guidance recommends that you should not take an extra dose to compensate for the one you forgot. You should simply resume treatment with your next regularly scheduled dose.

---

Q: Does the time of day I take Кардиолип matter for its effectiveness?

The official product instructions state that you can take your daily dose of Кардиолип at any time of day that is convenient for you. It does not need to be taken at a specific time, such as morning or night.

---

Q: Is it necessary to take Кардиолип with food, or can it be taken on an empty stomach?

Official instructions confirm that the medicine can be taken with or without food. You do not need to time your dose around meals for it to be effective.

---

Q: Can changing my diet make it possible to stop taking Кардиолип later?

The medicine is indicated to be used as an adjunct to diet and exercise, meaning it works in addition to lifestyle changes. Your healthcare provider assesses your risk profile; any decision to discontinue therapy, even after significant lifestyle changes, must be made only after a professional medical re-evaluation.

---

Q: Does Кардиолип affect my triglyceride levels as well as LDL cholesterol?

Yes, official studies show that the medicine is indicated for a comprehensive lipid-lowering effect. It works to reduce elevated levels of both LDL-cholesterol and triglycerides, and is also shown to help increase levels of HDL-cholesterol (the 'good' cholesterol).

---

Q: Is it normal to feel a bit tired or fatigued when first starting Кардиолип?

The official product information lists asthenia (general weakness) as one of the more common side effects reported in clinical trials. Experiencing some fatigue or tiredness is a documented reaction that may occur when starting this medication.

---

Q: What happens in the body if I suddenly stop taking Кардиолип?

The benefits of the medicine are achieved through continuous use. Discontinuing the medicine suddenly may result in cholesterol levels returning to pre-treatment levels and a loss of the protective benefits against cardiovascular risk.

---

Q: Can Кардиолип be used for people who have both high cholesterol and diabetes?

The medicine is generally not contraindicated for use in patients with diabetes, but official labeling notes that special consideration is needed. Because it may cause an increase in blood glucose levels, patients with risk factors for or a diagnosis of diabetes require close monitoring by a healthcare provider.

---

Q: Is there a generic version of Кардиолип available?

Yes, the active ingredient in Кардиолип, which is rosuvastatin calcium, is widely available in many regions as a generic product. Generic medicines must meet the same strict quality and effectiveness standards as the original branded drug.

---

Q: Does taking Кардиолип help increase HDL ('good') cholesterol?

In addition to lowering LDL ('bad') cholesterol and triglycerides, official product information confirms that the medicine also helps to increase the levels of HDL-cholesterol (High-Density Lipoprotein Cholesterol).

---

Q: What kind of research studies support the use of Кардиолип for heart disease prevention?

Clinical trials have been conducted to support the drug's use in high-risk populations. Studies have shown that it can slow the progression of atherosclerosis (hardening of the arteries) and is officially indicated to reduce the risk of major adverse cardiovascular events.

---

Q: Are there different strengths (milligrams) of Кардиолип tablets available?

Yes, the tablets are available in multiple dosage strengths to allow for flexibility in treatment. Official labeling confirms that the medicine is typically available in strengths such as 5 mg, 10 mg, 20 mg, and 40 mg.

---

Q: Can people with a family history of high cholesterol benefit from Кардиолип?

Yes, regulatory documents indicate that the medicine is indicated for use in adults who are at increased risk of cardiovascular disease based on specific risk factors. This includes a documented family history of premature coronary heart disease.

---

Q: Is it normal to have some aches in the joints or back while on this medication?

The official product information reports that muscle aches (myalgia) are a common adverse reaction. Based on clinical trial reporting, both joint pain (arthralgia) and back pain have also been reported by patients using this medicine.

Storage Requirements

Official regulatory documentation specifies that Кардиолип (Cardiolip) must be stored under controlled conditions to maintain its potency and stability:

• Temperature Control: Store the medicine at a controlled room temperature, generally defined as not above 25 C.
• Environmental Protection: The tablets must be stored in a dry place and protected from light.
• Handling Restriction: Do not freeze the product.

Constraint	Requirement
Container Rule	Must be kept in the original packaging to ensure protection from moisture and light.
Safety Mandate	The medicine must be stored out of the sight and reach of children.

Disposal Instructions

• Disposal Protocol: Unused or expired Кардиолип must be disposed of according to local governmental regulations.
• Environmental Rule: The medicine must not be placed into wastewater (do not flush down the toilet or pour down the sink) unless specific guidance from an authoritative body instructs otherwise.